Optinose Announces Departure of Acting Chief Financial Officer
09 déc. 2022 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
30 nov. 2022 07h00 HE
|
Optinose, Inc.
$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis Revised Note Purchase Agreement Extends Start of...
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
21 nov. 2022 08h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Proposed Public Offering of Common Stock and Warrants
21 nov. 2022 06h12 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
10 nov. 2022 07h00 HE
|
Optinose, Inc.
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps...
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
09 nov. 2022 15h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
07 nov. 2022 15h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
21 oct. 2022 07h00 HE
|
Optinose, Inc.
Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program ...
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
06 sept. 2022 12h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
11 août 2022 07h00 HE
|
Optinose, Inc.
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis...